Hospitalization for pulmonary embolism associated with antecedent testosterone or estrogen therapy in patients found to have familial and acquired thrombophilia

Table 4 Coagulation disorders in 24 cases (6 men [on testosterone] and 18 women [on estrogen]) who had testosterone/hormone therapy before PE, compared to 116 cases with PE but no hormone, no cancer (62 men, 54 women), and compared to 17 cancer cases (9 men, 8 women)

	Factor V	PTG	MTHFR	PAIG	Homocys-teine^a	Lupus anticoagulant	ACLA IgG	ACLA IgM
Abnormal range	TC,TT	TC,TT	TT	4G4G	umol/l	Positive	Dated^b	Dated^c
Hormone Cases (n = 24, 6 men on TT, 18 women on ET)	4/24 (17 %)	2/24 (8 %)	1/24 (4 %)	1/24 (4 %)	3/24 (13 %)	2/24 (8 %)	2/24 (8 %)	2/24 (8 %)
PE_no hormone, no Cancer (n = 116, 62 men, 54 women)	15/105 (14 %)	7/71 (10 %)			18/43 (42 %) **	17/68 (25 %)	1/61 (2 %)	5/58 (9 %)
Cancer (n = 17, 9 men, 8 women)	0/15 (0 %)				6/15 (40 %)	1/17 (6 %)	0/15 (0 %)	1/17 (6 %)

**p < .025, comparing with Hormone cases by Fisher’s test
^adated cut point for Homocysteine high: ≥ 15 (11/15/08-12/2/14); ≥10.4 (after 12/3/14)
^bdated cut point for IgG high: ≥ 23 GPL (before 10/31/12); ≥ 15 (after 11/1/12)
^cdated cut point for IgM high: ≥ 10 MPL (before 4/30/12); ≥ 13 (after 5/1/12)

ISSN: 2052-1839